Aktis Oncology, Inc. 8-K

What Happened

• Aktis Oncology, Inc. announced its financial results for the year ended December 31, 2025 via a press release dated March 30, 2026. The company filed a Current Report on Form 8‑K (filed March 31, 2026) to furnish that press release (Exhibit 99.1). The report was signed by Chief Financial Officer Kyle Kuvalanka on March 30, 2026.

Key Details

• Filing: Form 8‑K filed to disclose results of operations and financial condition (Item 2.02) and to furnish the press release as an exhibit (Item 9.01).
• Press release date: March 30, 2026; furnished as Exhibit 99.1 to the 8‑K.
• Reporting period: full year ended December 31, 2025.
• Authorized signatory: Kyle Kuvalanka, Chief Financial Officer (signed March 30, 2026).

Why It Matters

• The 8‑K tells investors that Aktis has publicly reported its 2025 earnings and business update; the press release will contain the specific revenue, net income/loss, cash position, and operational highlights investors use to assess performance and near‑term prospects.
• Investors should review the furnished press release (Exhibit 99.1) and related SEC filings (e.g., the company’s annual report) for the detailed earnings figures, guidance and any clinical or corporate updates that could affect the stock.